Nivolumab activity in relapsed Hodgkin's lymphoma.
Manjulika
M
Das
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects / Q000627:therapeutic use*; D018450:Disease Progression; D018572:Disease-Free Survival; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000473:pathology; D006801:Humans; D000077594:Nivolumab; D012008:Recurrence; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D000074322:Antineoplastic Agents, Immunological; D000077594:Nivolumab